TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

11A.44 Centers for Disease Control and Prevention (CDC). Adverse event data and revised American Thoracic
Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent
tuberculosis infection. Morb Mortal Wkly Rep 2003;52:735-9.
11A.45 Sneag DB et al. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts
of multidrug-resistant tuberculosis cases. Pediatr Infect Dis J 2007;26:1142-6.
11A.46 Schaaf HS. Evaluation of young children with adult multidrug resistant tuberculosis: a 30 months follow-up.
Pediatrics 2002;109:765-71.
11A.47 Ena J et al. Short course therapy with rifampin plus isoniazid compared with standard therapy with
isoniazid for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6.
11A.48 Cook PP et al. Safety and completion rate of short-course therapy for treatment of latent tuberculosis
infection. Clin Infect Dis 2006;43:271-5.
11A.49 Spyridis NP et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-months
regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of
an 11-year randomized study. Clin Infect Dis 2007;45:715-22.
11A.50 Vlaamse Vereniging voor Respiratoire gezondheidszorg en Tuberculosebestrijding (VRGT). Behandeling
van multiresistente tuberculose. Available at: http://www.vrgt.be/uploads/documentenbank/c0f5
6dd01ebc223b0cefa5fc1babd862.pdf. Accessed on August 9th 2010.
11A.51 Fonds des affections Respiratoires et pour l‘Education à la Santé (FARES). La tuberculose à germes
multirésistants. Available at: http://www.fares.be/documents/Faresfr.pdf. Accessed on August 9th
2010.
11A.52 Chaulk CP et al. Directly observed therapy for treatment completion of pulmonary tuberculosis. J Am
Med Assoc 1998;279:943-8.
11A.53 Bofinger JJ et al. Fever of unknown origin caused by tuberculosis. Infect Dis Clin North Am 2007;
21:947-62.
11A.54 Maartens G et al. Tuberculosis. Lancet 2007;370:2030-43.
11A.55 Connelly Smith K et al. A review of tuberculosis: reflections on the past, present and future of a global
epidemic disease. Expert Rev Anti Infect Ther 2003;1:483-91.
11A.56 Centers for Disease Control and Prevention (CDC). Treatment of tuberculosis. Morb Mortal Wkly
Rep 2003;52(RR-11):1-77.
11A.57 Myers JP. New recommendations for the treatment of tuberculosis. Curr Opin Infect Dis 2005;18:
133-40.
11A.58 Daley CL. Update in tuberculosis 2009. Am J Respir Crit Care Med 2010;181:550-5.
11A.59 Ralph AP et al. Tuberculosis into the 2010s: is the glass half full? Clin Infect Dis 2009;49:574-83.
11A.60 Campbell IA et al. Pulmonary tuberculosis: diagnosis and treatment. Br Med J 2006;332:1194-7.
11A.61 Rikimaru T. Endobronchial tuberculosis. Expert Rev Anti Infect Ther 2004;2:245-51.
11A.62 Golden MP et al. Extrapulmonary tuberculosis: an overview. Am Fam Physician 2005;72:1761-8.
11A.63 Jacob JT et al. Acute forms of tuberculosis in adults. Am J Med 2009;122:12-7.
11A.64 Sharma SK et al. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005;5:
415-30.
11A.65 Gardam M et al. Mycobacterial osteomyelitis and arthritis. Infect Dis Clin North Am 2005;19:819-30.
11A.66 Thwaites GE et al. Effect of antituberculosis drug resistance on response to treatment and outcome in
adults with tuberculous meningitis. J Infect Dis 2005;192:79-88.
11A.67 Donald PR bet al. Tuberculous meningitis. N Engl J Med 2004;351:1719-20.
11A.68 Patel VB et al. Multidrug resistant tuberculous meningitis in KwaZulu – Natal, South Africa. Clin Infect
Dis 2004;38:851-6.
11A.69 Rock RB et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol
Rev 2008;21:243-61.
11A.70 Donoghue SD et al. Intestinal tuberculosis. Curr Opin Infect Dis 2009;22:490-6.
11A.71 Jacob JT et al. Male genital tuberculosis. Lancet Infect Dis 2008;8:335-42.
11A.72 Deiss RG et al. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009;48:72-82.
11A.73 Thwaites GE et al. Dexamethasone for treatment of tuberculous meningitis in adolescents and adults.
N Engl J Med 2004;351:1741-51.
11A.74 Schoeman JF et al. Effect of corticosteroids on intracranial pressure, computed tomographic findings
and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99:226-31.
11A.75 Cruz AT et al. Treatment of tuberculosis in children. Expert Rev Anti Infect Ther 2008;6:939-57.
11A.76 Newton SM et al. Paediatric tuberculosis. Lancet Infect Dis 2008;8:498-510.
11A.77 Marais BJ et al. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir
Crit Care Med 2006;173:1078-90.
11A.78 Bergeron KG et al. Tuberculosis in pregnancy: current recommendations for screening and treatment
in the USA. Expert Rev Anti Infect Ther 2004;2:589-98.
11A.79 Swaminathan S et al. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010;50:1377-86.
11A.80 Sterling TR et al. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect
Dis 2010;50(suppl. 3):S223-30.
11A.81 Khan FA et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and
meta-analysis. Clin Infect Dis 2010;50:1288-99.
11A.82 Burman WJ et al. Treatment of HIV related tuberculosis in the era of effective antiretroviral therapy.
Am J Respir Crit Care Med 2001;164:7-12.
11A.83 Chukwuka Onyebunoh P et al. Treatment options for HIV-associated tuberculosis. J Infect Dis 2007;
196(suppl. 1):S35-45.
11A.84 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic
infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1-
207.
11A.85 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of
opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009;
58(RR-11):1-167.
11A.86 Nahid P et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care
Med 2007;175:1199-1206.
11A.87 Abdool Karim SS et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J
Med 2010;362:697-706.
11A.88 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral
agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/content
files/ AdultandAdolescentGL.pdf. Accessed on August 9th 2010.
11A.89 Drobniewski F et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST do-